Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly® subcutaneous injection ) for malignant lymphoma
Folia Pharmacologica Japonica · 2024
DOI: 10.1254/fpj.23076 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Folia Pharmacologica Japonica, 2024. Verfasst von Kana Takaura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Genmab K. K. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lymphoma, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Affairs, Genmab K. K.
Zitieren
APA
Takaura, K., Ando, H., & Ganoza, E. R. (2024). Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly® subcutaneous injection ) for malignant lymphoma. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.23076
Vancouver
Takaura K, Ando H, Ganoza ER. Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly® subcutaneous injection ) for malignant lymphoma. Folia Pharmacologica Japonica. 2024. doi:10.1254/fpj.23076
BibTeX
@article{Takaura2024,
author = {Takaura, Kana and Ando, Hiroshi and Ganoza, Edward Ramirez},
title = {Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly® subcutaneous injection ) for malignant lymphoma},
journal = {Folia Pharmacologica Japonica},
year = {2024},
doi = {10.1254/fpj.23076}
}
EUVIMED